Deep dives and investigations
you won't find anywhere else

Can Psilocybin Therapy Break Gambling Disorder? Three New Studies Aim to Find Out.

A flurry of new studies across Europe aims to open up research into treating this underserved group.

By Ella Glover

“There was no limit to the amount of hours I would spend on gambling and thinking about it,” says Robert, whose name has been changed for anonymity. “Basically, your whole day is consumed about what your next bet is going to be; your whole life revolves around that.”

Robert, a 62-year-old CEO in the sports industry, was gambling for the better part of 45 years before he was finally able to stop. 

He tried to quit numerous times and even managed to stop gambling for two years at one point, but with great effort. “I had to make a concerted effort not to open the newspaper on the racing page, or change the channel if there was a gambling ad on TV,” he says. He tried psychologists and began taking SSRIs. He went to a few sessions of Gamblers Anonymous. This was six years ago; he was determined to stop.

Then his cousin, who had been addicted to drugs for nearly 30 years, suggested they both try a psilocybin retreat. “I took it seriously,” he says. “It was done with the purpose of trying to solve the gambling issue.”

He went to a retreat in Somerset West, South Africa. In preparation for the retreat, he tapered off the SSRIs he’d been prescribed while trying to treat his gambling disorder, and fasted for two days, in accordance with the instructions given to him by the retreat leader. 

The session started at 7pm. Robert was nervous, having never taken drugs and, with no understanding of mushroom dosing, opted for the highest dose, which was 5 grams.  After about 45 minutes, it kicked in. “[The facilitator] had this background music playing, I can't remember, but it was the most beautiful sound that I've ever heard in my life,” he says. “The music was so crisp and crystal clear.” 

What followed was a beautiful, heroic trip. Robert connected with his mother, who died a year prior. He cried a “waterfall” of tears, then fell into the deepest, most beautiful laughing fit. He made contact with a higher power and felt at one with everything and everyone. 

It was pure bliss, but nothing, he recalls, in relation to gambling. 

Following the retreat, Robert restarted his antidepressants and went back to his life. While he noticed a change within himself, his gambling continued after the ceremony. The lesson didn’t land until about six months later in a dream.

“I went to one of these casino resorts and we were there as a family, and my mother-in-law said to me, ‘why don't you go to the casino?’ And I said to her, ‘no, I'm not going to go to the casino when the casino is calling me, I will go when I want to go,’” he recalls of his dream. “It was such a clear message that I woke up and I went and told my wife. I felt like I was in charge.” 

Robert never gambled again after this. “The burden of carrying that for so many years, having been lifted, is such a feeling of freedom, I can’t even explain it,” he says. “I wish I had [attended a mushroom ceremony] 30 years ago because I wasted so many years.”

The purchase, use, possession, manufacture, supply, and cultivation of psilocybin or psilocybin-containing mushrooms are illegal in most states and countries around the world, and retreats of this nature carry many risks. Robert didn’t attend a health screening, and tapering off antidepressants carried a big risk; not to mention the fact he took the highest dose as a first-time user with no tolerance. It’s also important to note that psilocybin is not a proven treatment for gambling disorder – yet. 

But, seven years after Robert’s transformative experience, researchers in London, Nantes, and Gibraltar are beginning to explore whether psilocybin-assisted therapy can treat gambling disorder. 

When Dr Rayyan Zafar began researching gambling disorder around eight years ago, alongside Dr David Erritzoe and colleagues at Imperial College London’s Centre for Psychedelic Research and Neuropsychopharmacology, the prospect of investigating psychedelics as a potential treatment for gambling disorder seemed distant.

“At that point, psychedelic research was still relatively small-scale and difficult to fund,” Zafar tells DoubleBlind. “Although early studies in depression had shown encouraging results, the larger controlled trials had yet to emerge, and there was very little research investigating psychedelics for behavioural addictions such as gambling disorder.”

Zafar and Erritzoe, who is now chief investigator of the PsiloGambling study, were investigating differences in reward processing and brain function associated with gambling disorder. Their research involved developing experimental tasks and using functional magnetic resonance imaging (fMRI) to examine how the brain responds to gambling-related stimuli and processes rewards.

Participants completed a cue-reactivity task involving gambling-related, nature, social and food-related video clips, allowing researchers to compare brain responses to gambling cues with other environmental and naturally rewarding stimuli. They also completed a roulette-based task inside an MRI scanner, designed to investigate reward processing, decision-making and neural responses to wins and losses.

“We always had in mind the possibility that, if the funding and scientific evidence came together, we could eventually use the tasks we’d developed to investigate the effects of psilocybin in people with gambling disorder,” Zafar says.

Now, Zafar is co-leading Imperial College London’s PsiloGambling study, which aims to investigate whether psilocybin can alter activity in brain networks involved in reward processing, craving and decision-making in people with gambling disorder.

The study represents an early step in a longer programme of research that could inform future randomised controlled trials and, ultimately, evaluations of whether psilocybin might have a role in treating gambling disorder within the UK’s National Health Service.

PsiloGambling is not the first study to investigate psilocybin-assisted interventions for addiction. Over recent years, several clinical trials have reported encouraging findings across substance use disorders, although the evidence remains preliminary and larger confirmatory studies are needed.

In a small randomized clinical trial conducted by researchers at the University of Alabama at Birmingham and published in JAMA Network Open in May 2026, 30% of participants who received psilocybin alongside structured psychotherapy reported complete abstinence from cocaine over the six-month post-treatment follow-up period, compared with none in the active placebo group. The trial involved 40 participants, highlighting the need for replication in larger samples.

Another pilot randomized clinical trial, published in JAMA Network Open in March 2026, involved 82 smokers. At six months, 40.5% of participants receiving psilocybin alongside cognitive behavioural therapy achieved biochemically verified prolonged abstinence from smoking, compared with 10% receiving nicotine patches alongside the same psychotherapy programme.

Earlier research in alcohol use disorder, published in JAMA Psychiatry in 2022, also found encouraging results. In a double-blind randomised trial involving 95 participants, those assigned to psilocybin-assisted psychotherapy experienced significantly fewer heavy drinking days over a 32-week follow-up period than those receiving an active placebo alongside psychotherapy. Average daily alcohol consumption was also lower in the psilocybin group.

Although these findings are promising, they come from relatively small studies involving different forms of addiction. They do not establish that psilocybin is effective for gambling disorder, nor can their findings be assumed to translate directly to behavioural addictions.

Nevertheless, they provided part of the scientific rationale for selecting psilocybin for the Imperial study.

“Gambling disorder shares substantial clinical and neurobiological features with substance use disorders, particularly in areas relating to reward processing, cue-reactivity and compulsive behaviour,” says Zafar. “That gives us a scientific basis for investigating whether some of the mechanisms being explored in substance addictions might also be relevant to gambling disorder.”

Psilocybin was also among the more clinically advanced psychedelic compounds, with an expanding body of research in depression and substance use disorders, making it a scientifically justified candidate for further investigation.

The study aims to recruit up to 35 adults with moderate to severe gambling disorder who are seeking or receiving treatment through the NHS National Gambling Clinic. The researchers initially envisaged a much smaller exploratory study, but subsequent research funding, including support associated with Zafar’s Wellcome-funded fellowship and the wider psychedelic research programme at Imperial, has enabled a more substantial investigation.

Participants will receive a single supervised 25 mg dose of psilocybin in a carefully controlled clinical research setting, accompanied by psychological preparation and support. Their existing clinical care through the National Gambling Clinic, which may include cognitive behavioral therapy, is distinct from the psychological support provided as part of the psilocybin research intervention.

The clinic’s treatment approach can involve motivational work, strategies to limit access to gambling, cognitive behavioural techniques addressing gambling-related beliefs and behaviours, relapse prevention, and consideration of the wider effects of gambling-related harm on families and relationships.

Researchers will use fMRI, electroencephalography (EEG), psychological questionnaires and other biological measures to investigate changes in brain activity, reward processing, gambling-related symptoms and psychological functioning following psilocybin administration.

Assessments will take place before dosing and at follow-up time points extending to 12 weeks, with the possibility of additional follow-up research for participants who provide appropriate consent.

The study began participant screening in August 2026. It is an open-label mechanistic study, meaning that all participants receiving the intervention know they are being given psilocybin, and there is no placebo or randomised control group.

Importantly, the study is designed primarily to investigate biological and psychological mechanisms rather than establish clinical efficacy. Although researchers will examine changes in gambling symptoms and behaviour, any improvements cannot be attributed to psilocybin alone without further controlled research.

“We’re particularly interested in whether psilocybin changes the brain’s response to gambling-related cues, and whether it also alters responses to natural rewards,” says Zafar. “By combining brain imaging with behavioural and clinical measures, we hope to better understand the mechanisms involved and whether these changes are associated with improvements in gambling-related symptoms.”

The researchers will also investigate individual differences in these responses, potentially helping to identify biological measures that could inform future research into treatment response.

At the University of Gibraltar, Pedro Romero is about to wrap up his first small study, in which four participants with gambling disorder took psilocybin at a retreat run by Heroic Heart Project UK. It’s observational research using surveys to track participants’ experiences over 12 months. 

Finding participants was difficult. The retreat was rescheduled once after around eight out of 10 participants dropped out days before, only for the same thing to happen again. “There's still a lot of stigma,” says Romero. “With gambling, there's a double stigma. I think if there were less, more people may be willing to try the experience.”

Romero originally trained as a psychologist and as a counselor in psychodynamic and cognitive behavioral therapy. He spent years working on harm reduction for gambling companies and charities, and he was the head of gambling therapy at the Gordon Moody Association, a large residential treatment program for people with gambling disorder in the UK.

“I was disheartened, because I was trying to help people affected by gambling related harm from different places,” he says. “I was working as an operator trying to make policies and protections for players, but that was very difficult. As a clinician, too, but you have a lot of relapses.” 

Gibraltar is one of the world’s biggest hubs for the online gambling industry, according to the Gibraltar Chronicle. Betting and gaming companies based there employ more than 3,400 people, over 10% of the territory’s workforce, and account for about 30% of its economy.

Romero says most of the approaches to treat gambling disorders are “very superficial” and don’t address underlying causes, with studies suggesting a large proportion of people with gambling disorder often have at least one additional psychiatric condition, such as anxiety. Approaches tend to include talk therapy, group support sessions, and digital blocking tools. 

Zafar seconds this. “Gambling disorder remains significantly underserved,” he says. “Although evidence-based psychological treatments are available, only a small proportion of people experiencing gambling-related harms access specialist support. There are currently no medications specifically licensed for gambling disorder in the UK, although some medicines can be considered off-label in selected cases.”

The National Gambling Clinic provides specialist NHS treatment, including psychological interventions, but many people experiencing gambling-related harm never access formal services.

Zafar hopes that research into the biological mechanisms underlying gambling disorder may eventually contribute to a broader range of evidence-based treatment options.

Gambling disorder also provides a particularly valuable opportunity to investigate some of the mechanisms associated with addiction. Although it does not involve the direct pharmacological effects of an addictive substance, it shares important clinical and neurobiological features with substance use disorders, including craving, compulsive behaviour, difficulties regulating gambling despite harmful consequences, and altered responses to reward-related cues.

“Gambling disorder offers a useful model for understanding addiction because we can investigate reward processing and compulsive behaviour without the direct pharmacological effects associated with ongoing substance consumption,” Zafar explains. “That gives us an opportunity to explore some of the mechanisms that may be shared across different forms of addiction.”

However, gambling disorder is not a completely unconfounded model. Psychiatric comorbidities, previous or concurrent substance use, medication exposure and individual differences can all influence brain function.

Not to mention, research into psilocybin-assisted psychotherapy for substance use disorders – such as for cocaine and nicotine – has produced encouraging findings. “These findings cannot simply be extrapolated to gambling disorder,” says Benoît Schreck, the lead researcher of Nantes University Hospital’s PASSENGER study, “but they provide a rationale for investigating the approach.

The pilot study has 30 participants and, unlike the Imperial study, is designed as a randomized, double-blind trial comparing two dose conditions alongside psychotherapy: a higher-dose group receiving 25 mg of psilocybin, potentially increased to 40 mg at the second administration according to the protocol, and a comparison group receiving 1 mg at both administrations. 

“Each participant follows a program lasting approximately three months, comprising ten sessions: four cognitive behavioural therapy sessions and two cycles consisting of preparation, supervised psilocybin administration and integration,” Schreck, tells DoubleBlind.

“Our primary outcome is the proportion of participants who complete the protocol,” he adds. “We also examine recruitment, acceptability, safety and preliminary changes in gambling behavior and other clinical measures.” Ideally, the pilot will establish whether a larger trial can be justified. While such a small study can’t provide a definitive answer about efficacy, he says, the hypothesis is that “psilocybin, within a structured therapeutic setting, might help some patients approach entrenched patterns of thinking and behavior differently and engage more deeply with psychotherapy”. 

But, Romero says psilocybin is not a silver bullet. “There's people who will get better but because their environment doesn't change they relapse. But it's something that can be really helpful to start that change.”

Robert, who used psilocybin outside of a medical framework, says he can’t completely attribute his change to the psilocybin trip, because he continued to take SSRIs. “There was a combination of the one and the other, and until today I continue to take those because I don't want to eliminate the fact that they could be also helping the process,” he says. 

What comes next is entirely dependent on the results of these studies. Romero hopes to do another observational study, this time with Ayahuasca but needs funding to get started, while studies in Nantes and at Imperial are at early stages. These exploratory investigations may help generate hypotheses and inform the design of larger, controlled clinical studies.

For PsiloGambling, the next steps will depend on the findings from the current study.

If the results suggest meaningful changes in reward-related brain activity, alongside encouraging clinical and behavioral signals, they could help inform future randomised controlled trials designed to establish whether psilocybin-assisted interventions are effective and safe for people with gambling disorder.

However, demonstrating changes in brain activity alone would not establish clinical benefit. Larger studies would be needed to determine whether any improvements in gambling-related symptoms are attributable to the intervention, whether those benefits are sustained, and which patients, if any, might benefit most.

In terms of psilocybin becoming a potential medicine for gambling disorder within the NHS, Zafar emphasizes that the field remains at an early stage.

“It’s still early days, and we need to be careful about making predictions,” he says. “Our first priority is to understand whether psilocybin produces meaningful changes in the brain mechanisms involved in gambling disorder, and whether these changes are associated with improvements in symptoms.

“If the findings are encouraging, the next step would be larger randomised controlled trials to establish whether the treatment is clinically effective and safe.

“Ultimately, I’d like to see us build an evidence base strong enough to consider psilocybin as a potential treatment option within the NHS. Whether that becomes possible, and on what timescale, will depend entirely on the quality of the evidence and the regulatory pathway. It’s an exciting prospect, but there’s still a considerable amount of work to do.”

💌 If you loved this email, forward it to a psychonaut in your life.


Editorial Process

DoubleBlind is a trusted resource for news, evidence-based education, and reporting on psychedelics. We work with leading medical professionals, scientific researchers, journalists, mycologists, indigenous stewards, and cultural pioneers. Read about our editorial policy and fact-checking process here.

Reply

Avatar

or to participate